ents to develop resistance? a. We can specify the type of resistance here, ie, to immunotherapy (PF-L1 inhibitors), chemotherapy (doxorubicin, paclitaxel, capecitabine, etc), and targeted therapy (PARP inhibitors, NTRK inhibitors, etc). **The time to resistance development in metastatic breast cancer varies substantially by therapy type and breast cancer subtype** , with median progression-free survival ranging from approximately 3-11 months across different treatment modalities. ## Immunotherapy (PD-1/PD-L1 Inhibitors) **For pembrolizumab plus chemotherapy in PD-L1-positive (CPS ≥10) triple-negative breast cancer** , the KEYNOTE-355 study demonstrated a progression-free survival benefit, though the exact median PFS varies by chemotherapy backbone used. In the IMpassion130 trial, **atezolizumab plus nab-paclitaxel improved progression-free survival by approximately 2.5 months in PD-L1-positive TNBC** (>1% expression).[1] However, the overall survival analysis showed no significant difference between treatment groups, though it suggested a clinically meaningful OS benefit of about 10 months with atezolizumab plus nab-paclitaxel in the PD-L1-positive population.[1] In a real-world cohort of TMB-high metastatic breast cancer patients treated with immune checkpoint inhibitors, **median progression-free survival was only 3.17 months (95% CI 2.27-5.5)** across all patients, though this was a heavily pretreated population (median 5th line therapy).[2] Notably, shorter PFS was significantly associated with later treatment lines (HR 1.22 per line, 95% CI 1.11-1.36, p=0.0001).[2] ## Chemotherapy **Time to resistance varies considerably by agent and breast cancer subtype:** **Doxorubicin-containing regimens:** In a large reference cohort of 1,581 patients with metastatic breast cancer, **median progression-free survival was 11.5 months (95% CI 10.9-12.3 months)** with doxorubicin-containing combination chemotherapy.[3] Median overall survival was 21.3 months.[3] **Paclitaxel:** In metastatic breast cancer patients receiving paclitaxel-containing chemotherapy, **median time to treatment failure was 11.2 months (95% CI 9.5-12.9) in patients who developed early peripheral neuropathy** versus 5.7 months (95% CI 4.6-6.8) in those without early neuropathy.[4] **Capecitabine:** As monotherapy for HER2-normal metastatic breast cancer, **median progression-free survival was 4.3 months overall** , with significant differences by ER status: 5.3 months for ER-positive versus 2.5 months for ER-negative disease (p=0.006).[5] Median overall survival was 14 months overall, 17.8 months for ER- positive versus 7.6 months for ER-negative disease (p≤0.0001).[5] Treatment schedule influences resistance development. **Intermittent doxorubicin exposure induced resistance more readily than continuous exposure** , with ER-positive MCF-7 cells developing resistance earlier and at higher levels compared to triple-negative MDA-MB-231 cells.[6] ## PARP Inhibitors **For olaparib and talazoparib in germline BRCA1/2-mutant metastatic breast cancer** , these agents are recommended as category 1, preferred first-line therapy for triple-negative disease with PD-L1 CPS [7] While specific median PFS data varies by trial, **approximately 40-60% of patients develop resistance to PARP inhibitors** , with BRCA reversion mutations detected in 43% of breast cancer patients at progression on olaparib (compared to only 9% receiving chemotherapy).[8] **BRCA reversion mutations can be detected in circulating tumor DNA before clinical progression** in some cases, with 10 patients showing detectable reversions prior to radiographic progression.[8] When reversions are detected before commencing subsequent treatment, they associate with significantly shorter time to progression.[8] ## NTRK Inhibitors **For larotrectinib in NTRK fusion-positive solid tumors** (including breast cancer), an integrated analysis showed **median progression-free survival of 11 months (95% CI 8.0-14.9)** and median overall survival of 21 months (95% CI 14.9 to not estimable). [9] **For entrectinib** , updated analysis demonstrated **median progression-free survival of 13.8 months (95% CI 10.1-19.9)** and median overall survival of 33.8 months (95% CI 23.4-46.4).[9] The median duration of response was 20.0 months (95% CI 13.0-38.2).[9] ## Clinical Context The likelihood and timing of resistance development is influenced by multiple factors including treatment line, tumor burden, receptor status, and prior therapies. **In HR+/HER2- metastatic breast cancer receiving first-line CDK4/6 inhibitor plus endocrine therapy, resistance inevitably develops in most patients despite approximately 20% achieving long-term disease control at five years** . After CDK4/6 inhibitor progression, only 40.5% of patients achieved at least 6 months of benefit from second-line therapy. Would you like me to summarize the mechanisms underlying these different timelines to resistance, or discuss strategies for predicting and potentially delaying resistance development based on biomarkers or treatment sequencing? Would you like me to review the latest evidence on clinical and molecular biomarkers that can predict early resistance to these therapies in metastatic breast cancer, and how they might guide personalized treatment selection or sequencing? ### References 1. Breast Cancer. Loibl S, Poortmans P , Morrow M, Denkert C, Curigliano G. Lancet (London, England). 2021;397(10286):1750-1769. doi:10.1016/S0140-6736(20)32381-3. 2. Immune checkpoint inhibition for the treatment of metastatic breast cancer with high tumor mutational burden: Real world clinical and genomic correlates of response. Mai N, Safonov A, Marra A, et al. Journal of Clinical Oncology. 2024;42(Suppl 16):1078. doi:10.1200/JCO.2024.42.16_suppl.1078. 3. Results and Long Term Follow-Up for 1581 Patients With Metastatic Breast Carcinoma Treated With Standard Dose Doxorubicin-Containing Chemotherapy: A Reference. Rahman ZU, Frye DK, Smith TL, et al. Cancer. 1999;85(1):104-11. doi:10.1002/(sici)1097-0142(19990101)85:13.0.co;2-r. 4. The Early Onset of Peripheral Neuropathy Might Be a Robust Predictor for Time to Treatment Failure in Patients With Metastatic Breast Cancer Receiving Chemotherapy Containing Paclitaxel. Fukada I, Ito Y , Kobayashi K, et al. PloS One. 2017;12(9):e0184322. doi:10.1371/journal.pone.0184322. 5. Effect of Capecitabine as Monotherapy for HER2 Normal Metastatic Breast Cancer. Knudsen AM, Modvig MW, Vogsen M, Kodahl AR. Medical Oncology (Northwood, London, England). 2024;41(5):99. doi:10.1007/s12032-024- 02356-y. 6. Treatment Schedule and Estrogen Receptor-Status Influence Acquisition of Doxorubicin Resistance in Breast Cancer Cells. Ponnusamy L, Mahalingaiah PKS, Singh KP . European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences. 2017;104:424-433. doi:10.1016/j.ejps.2017.04.020. 7. Breast Cancer. National Comprehensive Cancer Network. Updated 2025-10-16. 8. Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches. Dilmac S, Ozpolat B. Cancers. 2023;15(14):3642. doi:10.3390/cancers15143642. 9. Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. Henry NL, Somerfield MR, Dayao Z, et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2022;40(27):3205-3221. doi:10.1200/JCO.22.01063. 11.